Retapamulin Activity Against Pediatric Strains of Mupirocin-resistant Methicillin-resistant Staphylococcus aureus

Pediatr Infect Dis J. 2021 Jul 1;40(7):637-638. doi: 10.1097/INF.0000000000003123.

Abstract

Retapamulin activity against 53 isolates obtained from a mupirocin-resistant community-acquired methicillin-resistant Staphylococcus aureus pediatric disease cluster was evaluated using broth microdilution. All strains were susceptible to retapamulin with minimum inhibitory concentrations ≤ 0.5 μg/mL. DNA sequence analysis of rplC and cfr identified one rplC strain variant that did not demonstrate reduced phenotypic susceptibility to retapamulin. These results demonstrate that retapamulin may be a useful alternative therapy for mupirocin-resistant community-acquired methicillin-resistant S. aureus, especially in disease clusters.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Anti-Bacterial Agents / pharmacology*
  • Bridged Bicyclo Compounds, Heterocyclic / pharmacology*
  • Child
  • Child, Preschool
  • Community-Acquired Infections / drug therapy
  • Community-Acquired Infections / microbiology
  • Diterpenes / pharmacology*
  • Humans
  • Infant
  • Infant, Newborn
  • Methicillin-Resistant Staphylococcus aureus / drug effects*
  • Methicillin-Resistant Staphylococcus aureus / genetics
  • Microbial Sensitivity Tests
  • Mupirocin / pharmacology*
  • Sequence Analysis, DNA
  • Staphylococcal Infections / drug therapy*

Substances

  • Anti-Bacterial Agents
  • Bridged Bicyclo Compounds, Heterocyclic
  • Diterpenes
  • retapamulin
  • Mupirocin